CHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies CHROMOCELL THERAPEUTICS CORPORATION 2 This presentation of Chromocell Therapeu

CHROMOCELL THERAPEUTICS

CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies

CHROMOCELL THERAPEUTICS

CORPORATION 2 This presentation of Chromocell Therapeutics Corporation ("we", "us", "our"

or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation

Reform Act and other securities laws. Words such as "anticipate," "believe," "continue," "could,"

"estimate," "expect," "intend," "may," "plan," "potential,"

"predict, "project," "seek," "should," "target," "will," "would"

or similar expressions and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements

reflect management's current expectations, are based on judgments and assumptions, are inherently uncertain and are subject

to risks, uncertainties and other factors, which could cause the Company's actual results, performance or achievements to

differ materially from expected future results, performance or achievements expressed or implied in those forward-looking statements.

Examples of these forward-looking statements and the related risks, uncertainties and other factors include, but are not limited

to, the following: the timing, progress and results of preclinical and clinical trials for CC8464, its estimates regarding the

potential market opportunity for CC8464, its ability to develop CC8464 and future compounds, its ability to protect its intellectual

property and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive

position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited

to, the Company's limited operating history, the Company's ability to develop CC8464, the Company's ability

to establish its market development capabilities to commercialize its products and generate any revenue, and the Company's

ability to obtain regulatory approval of CC8464. Forward-looking statements are provided to allow potential investors the opportunity

to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions

as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should

not be placed on them. Any forward-looking statement in this presentation, in any related presentation supplement and in any related

free writing presentation reflects our current view with respect to future events and is subject to these and other risks, uncertainties

and assumptions relating to our business, results of operations, industry and future growth. You should read this presentation

with the understanding that our actual future results may be materially different from any future results expressed or implied

by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking

statements for any reason, even if new information becomes available in the future. Legal Disclaimer

CHROMOCELL THERAPEUTICS

CORPORATION 3 Key data points (as of 6/24/24, except where noted) Founded 2002 NYSE American Ticker CHRO Stock Price $1.30 Shares

Outstanding Fully Diluted ~5.8M Cash, Cash Equivalents (as of 3/31/24) ~$3.8M Total Debt (as of 3/31/24) ~$1.5M Investment to

Date >$40M IPO 2024 - Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus

on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system ("PNS").

- NaV1.7 is a genetically validated target, and there is a growing interest in NaV blockers as a safe and effective therapeutic.

- Dr. Stephen Waxman, head of our Scientific Advisory Board, is one of the foremost experts in NaV research; his work contributed

to demonstrating that NaV1.7 sodium channels play major roles in pain signaling. - Prior licensing and collaboration agreement

with Astellas Pharma Inc. ("Astellas") supported the pre-clinical and Phase I studies. - Clinical programs: -

CC8464 (oral) - idiopathic small fiber neuropathy ("ISFN"), erythromelalgia ("EM") and other forms

of neuropathic pain - CT2000 (topical) - acute and chronic eye pain Corporate Profile

CHROMOCELL THERAPEUTICS

CORPORATION 4 EXPERIENCED TEAM MILESTONES DEVELOPMENT PROGRAMS NOVEL PAIN THERAPEUTIC INTELLECTUAL PROPERTY LARGE COMMERCIAL OPPORTUNITY

COMMERCIALIZATION Novel, peripherally restricted, NaV1.7 receptor target does not penetrate the CNS or cause euphoria and addresses

indications with significant unmet need CC8864: Oral delivery of a NaV1.7 therapy initially targeting iSFN/EM CT2000: Pre-clinical

program for treatment of eye pain through topical administration Strong preclinical data demonstrating reduced pain in animal

models; well tolerated in Phase I studies with the exception of a skin rash that occurred mostly at higher doses Highly experienced

group of experts in pain management and research; CEO has successfully shepherded more than 15 successful M&A/licensing transactions

with Fortune 50 companies Patent protection in North America and parts of Europe and Asia; expect to receive orphan designation

for lead indications of CC8464, providing additional protective rights Overall, US pain treatment is a $78B per year industry

Build a pipeline of non-opioid pain treatment programs; after achieving Phase II success, review out-licensing / sales / JV options

Investment Highlights

CHROMOCELL THERAPEUTICS

CORPORATION 5 Management Team Frank Knuettel | CEO & Chief Financial Officer Mr. Knuettel has 30 years of management experience

in growing early-stage companies. He has raised more than $300 million via venture, public equity and debt offerings and managed

more than 15 mergers and acquisition transactions along with large-scale licensing transactions with fortune 50 companies. Mr.

Knuettel holds numerous board positions, at both public and private companies, including ECOM Medical, Relativity Acquisition

Corp. (RACY) and Capstone Technologies Group Inc (OTC: CATG). He holds an MBA from The Wharton School and a BA from Tufts University.

Dr. Eric Lang | Chief Medical Officer Dr. Lang is an Anesthesiologist and Pain Management Specialist with over 25 years of experience

in the pharmaceutical industry, who has had broad-based drug development expertise in multiple therapeutic areas. Dr. Lang has

experience in designing development programs from early translational stages through phase III including the successful filing

of several recent INDs and NDAs. Dr. Lang began his career with J&J and later worked for Novartis, Javelin Pharmaceuticals,

Grunenthal USA, Covance, EnteraBio and Nevakar Inc. Dr. Lang received his MD from Ben Gurion University, Israel and completed

post graduate training at Emory University in Atlanta. SIMON CHANDLER, PHD | Chief Medical Officer Dr. Chandler has specialized

in Ophthalmology for over 30 years in both academic roles and industry. He has held a leading role in 4 successful ophthalmic

drug approvals in the US, Europe and Japan in for glaucoma, pain, retinal disease, myopia and dry eye. Dr. Chandler has expertise

in ophthalmic trial designs and conduct globally, from proof-of-concept to registration and post-approval. He began in genetic

engineering at Sangamo and later worked at Santen, ISTA, Bausch and Lomb, Allergan and Vyluma. He earned his Ph.D at Southampton

Medical School and completed post-doctoral training at the NIH working on epigenetics

CHROMOCELL THERAPEUTICS

CORPORATION 6 CHROMOCELL THERAPEUTICS CORPORATION Clinical & Competitive Background

CHROMOCELL THERAPEUTICS

CORPORATION 7 Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain NaV1.1 NaV1.2 NaV1.6 NaV1.8

NaV1.9 NaV1.7 NaV1.5 NaV1.4 Sodium Channels (NaVs) and Pain Pain Perception Sodium channels play a crucial role in pain transmission.

- Action potentials are the electrical waves that the body uses to send information through nerves. - These action potentials

are created through fluxes of various ions, including sodium ions, across the nerve fiber wall. - NaV1.7 is though to be

responsible for a slow initial upward start of the action potential that leads to a rapid upward component that is thought to

be mediated by NaV1.8. - In this respect, NaV1.7 and NaV1.8 may work together to allow a signal to progress through a nerve

fiber. Dr. Stephen Waxman and his lab discovered the genetic correlation between pain and NaV, NaV1.7, NaV1.8 and sodium channels

CHROMOCELL THERAPEUTICS

CORPORATION 8 Insensitivity to Pain Lack of NaV1.7 (Rare condition initially described in a family from Pakistan) Severe Pain

Excessive NaV1.7 activity (e.g. Erythromelalgia) Congenital Insensitivity to Pain Spectrum of NaV1.7 Activity Severe Pain Why

NaV1.7 is a Good Target for Pain Treatment Genetic validation suggests NaV1.7 suppression is an attractive pharmacological target

CHROMOCELL THERAPEUTICS

CORPORATION 9 NaV Sodium Channels Development for Pain 2004 2006 2015 2016-2019 2021 2024 Erythromelalgia - the first human

disorder linked to an ion channel mutation w/ chronic neuropathic pain linking to SCN9A gene - published in the Journal of Medical

Genetics Waxman's lab publishes paper in Journal of Neuroscience, demonstrating mutations enhanced function of NaV1.7 sodium

channels, preferentially expressed within peripheral neurons Waxman's lab reports gainof- function mutations of NaV1.8 in

are associated with pain in humans Chromocell demonstrates efficacy in multiple animal models and completes 3- month toxicology

in 2 species Chromocell synthesizes a NaV1.7 inhibitor that is highly specific for NaV1.7 and is peripherally restricted and does

not pass the blood brain barrier Vertex reported that VX-548 targeting NaV1.8 was studied in registrational trials (evaluating

effects on pain in patients who had undergone bunionectomy or abdominoplasty surgeries) and significantly reduced reported pain

scores (Jones et al., 2023) Chromocell enters into collaboration agreement w/ Astellas on the codevelopment of CC8464. Chromocell

completes 3 Phase I trials in healthy volunteers, Astellas completes 1 additional Phase I trial CC8464 is well tolerated except

for a skin rash that is determined to be a delayed type hypersensitivity Cambridge Univ. reports that an reaction SCN9A mutation

was associated with a congenital insensitivity to pain Waxman publishes a book called Chasing Men on Fire: The Story of the Search

for a Pain Gene which describes the cause of EM. 2012 2016 Phase 1 trial compared Vertex VX-150 NaV1.8 pro-drug, to placebo. First

in human NaV1.8 pain study. (Hijma et al., 2021). 2023 Following a spin off and IPO in 2024, Chromocell prepares to relaunch CC8464

program for the treatment of chronic pain treatment and begins formulation of CT2000 (eye drops containing a NaV1.7 inhibitor)

for the treatment of eye pain

CHROMOCELL THERAPEUTICS

CORPORATION 10 Preclinical - Potent (nM) inhibitor of human NaV1.7; Subtype selective - Demonstrated in vivo efficacy